DLQI and PASI improve together initially and during re-treatment with etanercept - 21/08/11
Craig Leonardi, MD, Saint Louis University, St. Louis, MO, United States; Steven R. Feldman, MD, PhD, Wake Forest University, Winston-Salem, NC, United States; Tiffani K Hamilton, MD, Atlanta Dermatology, Vein, and Research Center, Alpharetta, GA, United States; Seth R. Stevens, MD, Amgen, Inc., Thousand Oaks, CA, United States
Le texte complet de cet article est disponible en PDF. P2735 Dr. Leonardi is a member of Amgen's clinical advisory board and speakers bureau and is a principal investigator in Amgen clinical trials. Dr. Feldman has received speaking, consulting, and grant support from Amgen. Dr. Hamilton has been a principal investigator in Amgen clinical trials and a member of Amgens speaker's bureau. Research supported by Immunex Corporation, a wholly owned subsidiary of Amgen, Inc., and by Wyeth Research |
Vol 52 - N° 3S
P. P180 - mars 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?